Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG)

Virtu Financial LLC purchased a new position in FibroBiologics, Inc. (NASDAQ:FBLG) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,862 shares of the company’s stock, valued at approximately $30,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FBLG. The Manufacturers Life Insurance Company bought a new position in shares of FibroBiologics in the third quarter worth approximately $32,000. Jane Street Group LLC purchased a new stake in FibroBiologics during the 3rd quarter valued at $37,000. Intech Investment Management LLC bought a new stake in FibroBiologics in the 4th quarter worth $25,000. Raymond James Financial Inc. purchased a new position in shares of FibroBiologics in the fourth quarter valued at about $37,000. Finally, Barclays PLC raised its stake in shares of FibroBiologics by 363.2% during the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after acquiring an additional 31,331 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research note on Tuesday. Rodman & Renshaw initiated coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, D. Boral Capital reissued a “buy” rating and set a $16.00 target price on shares of FibroBiologics in a research note on Tuesday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Performance

Shares of FBLG opened at $0.86 on Wednesday. The company has a 50-day simple moving average of $1.28 and a two-hundred day simple moving average of $2.14. FibroBiologics, Inc. has a one year low of $0.86 and a one year high of $13.59.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.